Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients
2014-001372-66Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jul 2014
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tacrolimus in kidney transplant immunosuppression (2 arms), sponsored by Erasmus MC. Primary endpoints: Feasibility: BPAR rate at 15 months and Primary immunological measurements. Started Jul 2014; status: active.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2014-001372-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001372-66.